September 12, 2018 / 12:43 PM / 7 days ago

BUZZ-Bausch Health Companies: Rises on patent settlement with Actavis

** Drugmaker’s U.S.-listed shares up ~8 pct at $22.25 premarket, after co settles an IP litigation

** Co has resolved intellectual property litigation related to its bowel disorder drug, Xifaxan, with Actavis Laboratories FL Inc; the deal will not have any financial obligation

** Actavis can market a royalty-free generic version of Xifaxan, subject to approval from U.S. FDA ** Actavis also has another option to market an authorized generic version with drug supplied by BHC’s subsidiary Salix Pharma

** Allergan Plc is the parent co of Actavis; there wasn’t any trading of AGN shares premarket

** Up to Tuesday’s close, AGN stock up ~15 pct this year (Reporting by Aakash Jagadeesh Babu in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below